Bosentan for patients with chronic thromboembolic pulmonary hypertension

European Journal of Internal Medicine

Volumn 20, Issue 1, 2009, Pages 24-29

  Vassallo, Fabio Giuseppe ^a   Kodric, Metka ^a   Scarduelli, Cleante ^b   Harari, Sergio ^c   Potena, Alfredo ^d   Scarda, Angelo ^a   Piattella, Marco ^d   Cassandro, Roberto ^c   Confalonieri, Marco ^a  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b Hospital of Mantova   (Italy)

^c S Giuseppe Hospital   (Italy)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Bosentan; Chronic thromboembolic pulmonary hypertension; Endothelin; Pulmonary hypertension; Six minutes walking test; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; DIURETIC AGENT;

ADULT; AGED; ARTERIAL GAS; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MALE; MULTICENTER STUDY; OXYGEN TENSION; OXYGENATION; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SIDE EFFECT; WALKING;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DIURETICS; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; SULFONAMIDES; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 60649107129     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.03.008     Document Type: Article

References (30)

1. Fedullo P.F., Auger W.R., Kerr R.M., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 345 20 (2001) 1465-1472
2. Pengo V., Lensing A.W.A., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
3. Doyle R.L., MacCrory D., Chennick R.N., Simonneau G., and Conte J. Surgical treatment/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 63s-71s
4. Dartevelle P., Fadel E., Mussot S., Chapelier A., Hervé P., de Perrot M., et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 23 4 (2004) 637-648
5. Ulrich S., Speich R., Domenighetti G., Geiser T., Aubert J.D., Rochat T., et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med Wkly 137 (2007) 573-580
6. Kunieda T., Nakanishi N., Satoh T., Kyotani S., Okano Y., and Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 38 (1999) 543-546
7. Suntharalingam J., Machado R.D., Sharples L.D., Toshner M.R., Sheares K.K., Hughes R.J., et al. Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax 62 (2007) 617-622
8. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) S40-S47
9. Bresser P., Pepke-Zaba J., Jaïs X., Humbert M., and Hoeper M.M. Medical therapies for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3 7 (2006) 594-600
10. American Thoracic Society and European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment; international consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
11. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 144 (1991) 1202-1218
13. ATS statement single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 152 (1995) 2185-2198
14. Hoeper M.M., Kramm T., Wilkens H., Schulze C., Schafers H.J., Welte T., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2363-2367
15. Bonderman D., Nowotny R., Skoro-Sajer N., Jakowitsch J., Adlbrecht C., Klepetko W., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2599-2603
16. Hughes R.J., Jais X., Bonderman D., Suntharalingam J., Humbert M., Lang I., et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 28 (2006) 138-143
17. Seyfarth H.J., Hummerschmidt S., Pankau H., Winkler J., and Wirtz H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration. 74 3 (2007) 287-292
18. Jamieson S.W., Kapelanski D.P., Sakakibara N., Manecke G.R., Thistlethwaite P.A., Kerr K.M., et al. Pulmonary endarterectomy: experience and lessons learned in 1500 cases. Ann Thorac Surg 76 (2003) 1457-1462
19. Jamieson S.W. Pulmonary thromboendarterectomy. Heart 79 (1998) 118-120
20. Moser K.M., Auger W.R., and Fedullo P.F. Chronic major-vessel thrombotic pulmonary hypertension. Circulation 81 (1990) 1735-1743
21. Riedel M., Stanek V., Widinsky J., and Prerovsky I. Long term follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest 81 (1982) 151-158
22. Hoeper M.M., Mayer E., Simonneau G., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. Circulation 113 (2006) 2011-2020
23. Kim N.H., Fesler P., Channick R.N., Knowlton K.U., Ben-Yehuda O., Lee S.H., et al. Preoperative partitioning of pulmonary vascular resistance correlates with early outcome after thromboendarterectomy for chronic thromboembolic pulmonary hypertension. Circulation 109 (2004) 18-22
24. Reesink H.J., Meijer R.C., Lutter R., Boosma F., Jansen H.M., Kloek J.J., et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circulation J 8 (2006) 1058-1063
25. Bauer M., Wilkens H., Langer F., Schneider S.O., Lausberg H., and Schäfers H.J. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105 (2002) 1034-1036
26. Bonderman D., Skoro-Sajer N., Jakowitsch J., Adlbrecht C., Dunkler D., Taghavi S., et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 115 (2007) 2153-2158
27. Archibald C.J., Auger W.R., Fedullo P.F., Channick R.N., Kerr K.M., Jamieson S.W., et al. Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 160 (1999) 523-528
28. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
29. Hinderliter A.L., Willis IV P.W., Barst R.J., Rich S., Rubin L.J., Badesch D.B., et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 95 (1997) 1479-1486
30. Galie N., Humbert M., Vachiery J.L., Vizza C.D., Kneussl M., Manes A., et al., Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502